Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220289 | 0.98 | MTNR1A (0.44) | MTNR1ANQO2TDP1GPR84CYP1A2 | |
| SCHEMBL11842602 | 0.98 | MTNR1A (0.44) | MTNR1ANQO2TDP1GPR84CYP1A2 | |
| SCHEMBL143127 | 0.95 | MTNR1A (0.46) | MTNR1ANQO2TDP1GPR84CYP1A2 | |
| SCHEMBL7176829 | 0.90 | HPRT1 (0.44) | MTNR1ANQO2TDP1GPR84MCL1 | |
| SCHEMBL7184367 | 0.89 | HPRT1 (0.42) | MTNR1ANQO2TDP1GPR84MCL1 | |
| SCHEMBL143457 | 0.87 | MTNR1A (0.49) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL7182829 | 0.85 | MTNR1A (0.39) | MTNR1ANQO2GPR84SIGMAR1 | |
| SCHEMBL7176160 | 0.85 | HPRT1 (0.45) | MTNR1ANQO2TDP1GPR84CYP1A2 | |
| SCHEMBL9800436 | 0.84 | CYP1A2 (0.58) | MTNR1ANQO2TDP1GPR84CYP1A2 | |
| SCHEMBL7189734 | 0.83 | MTNR1A (0.38) | MTNR1ANQO2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966456-B1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2003-04-02 | — | — | EP | claimed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | claimed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | claimed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | claimed |
| US-7750155-B2 | Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2099756-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLA PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-5066816-A | PROCESSES FOR PREPARING OPTICALLY ACTIVE 3,4-DIHYDRO-3,4-EPOXY-2H-1-BENZOPYRAN COMPOUNDS AND INTERMEDIATES THEREFOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1991-11-19 | — | — | US | disclosed |
| EP-0456266-A1 | Method for preparing optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compounds, intermediates therefor and uses thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1991-11-13 | — | — | EP | disclosed |
| EP-0386640-A2 | Processes for preparing optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compounds and intermediates therefor | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4576753-A | MICROBIOCIDES, ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-18 | — | — | US | disclosed |
| US-4472309-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-09-18 | — | — | US | disclosed |
| US-4304718-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-08 | — | — | US | disclosed |
| US-4264498-A | REACTED WITH AN ACID, ITS ACID HALIDE, OR ANHYDRIDE IN THE PRESENCE OF BORON TRIHALIDE AND AN ORGANIC BASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-04-28 | — | — | US | disclosed |
| US-4181800-A | ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC6, HDAC5 | MTNR1A 3518/4885NQO2 287/4885TDP1 388/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | MTNR1A 942/4885NQO2 1505/4885TDP1 1981/4885 |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC11, HDAC2 | MTNR1A 3357/4885NQO2 857/4885TDP1 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.